Kelonia
Delivering on the Promise of Genetic Medicine
- Headquarters
- Boston, Massachusetts
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Website
- keloniatx.com
- Total Funding
- $50.0M
- Last Round
- $50.0M Series AApr 2022
About
Kelonia Therapeutics is a clinical-stage gene therapy company headquartered in Boston, Massachusetts, focused on in vivo gene delivery to advance a new era of genetic medicines. Founded in 2021, Kelonia is developing proprietary delivery platforms designed to address a broad range of genetic diseases with greater accessibility and scalability than ex vivo approaches. The company's pipeline targets diseases amenable to gene correction, with preclinical and early clinical programs spanning oncology and rare genetic conditions. Kelonia is led by founder and CEO Kevin Friedman, PhD, and backed by investors including Alta Partners and Venrock. The company has assembled a multidisciplinary team of scientists, clinicians, and industry veterans from leading pharma and biotech organizations.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account